Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.
The future of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the treatment of metastatic castration-resistant prostate cancer (mCRPC) is promising in light of encouraging results from recent clinical studies.
Since the approval of immune checkpoint inhibitors (ICIs) as standard of care in the second-line setting for metastatic urothelial carcinoma, new approaches on how clinicians manage this condition are emerging.
Studies have demonstrated that robot-assisted radical cystectomy (RARC) is as effective and has a cost advantage compared with open cystectomy for the management of urologic cancers.
Recent research has revealed various potential biomarkers for metastatic castration-resistant prostate cancer (mCRPC), but several challenges remain in fully utilizing them in clinical practice.
Targeted antibiotic prophylaxis – after a rectal swab to identify specific intestinal flora – does not appear to significantly impact the risk of urinary sepsis following a transrectal ultrasound (TRUS)-guided prostate biopsy, according to a recent study.